# Zeria Pharmaceutical clinical trials: 23 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 23 trials with Zeria Pharmaceutical as lead sponsor, 0 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Zeria Pharmaceutical: 23 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/zeria-pharmaceutical

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 23
- Recruiting or not yet: 0
- Read on: November 19, 2026

## Trials

The 23 newest of 23, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 9, 2021 | NCT04955678 | A Comparative Study of ZG-801 and Placebo in Patients With Hyperkalemia | Zeria Pharmaceutical | Phase 3 | Completed | Hyperkalemia | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04955678) |
| August 25, 2020 | NCT04526119 | A Phase III Trial of Z-338 in Paediatric Patients With Functional Dyspepsia | Zeria Pharmaceutical | Phase 3 | Completed | Functional Dyspepsia | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04526119) |
| January 10, 2019 | NCT03799926 | Exploratory Study of ZG-801 for the Treatment of Hyperkalemia | Zeria Pharmaceutical | Phase 2 | Completed | Hyperkalemia | 184 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03799926) |
| March 23, 2018 | NCT03476018 | Trial to Optimally Show the Pharmacological Action of Z-100 | Zeria Pharmaceutical | Phase 3 | Completed | Cervical Cancer | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03476018) |
| July 11, 2016 | NCT02828319 | Clinical Study of Z-213 in Subjects With Iron-deficiency Anemia | Zeria Pharmaceutical | Phase 3 | Completed | Iron Deficiency Anemia | 39 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02828319) |
| April 7, 2016 | NCT02731534 | Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia | Zeria Pharmaceutical | Phase 3 | Completed | Iron Deficiency Anemia | 238 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02731534) |
| December 1, 2015 | NCT02618629 | Mass Balance and Metabolism Study of 14C-Z-215 | Zeria Pharmaceutical | Phase 1 | Completed | Healthy Male Subjects | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02618629) |
| July 28, 2015 | NCT02509923 | To Evaluate Pharmacokinetics and Pharmacodynamics of Z-215 in Healthy Male Subjects | Zeria Pharmaceutical | Phase 1 | Completed | Healthy | 54 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02509923) |
| June 4, 2015 | NCT02463643 | To Evaluate Efficacy and Safety of Z-215 in Erosive Esophagitis | Zeria Pharmaceutical | Phase 2 | Completed | Esophagitis, Reflux | 503 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02463643) |
| September 23, 2014 | NCT02247232 | Randomized Study of Z-100 Plus Radiation Therapy to Treat Cervical Cancer | Zeria Pharmaceutical | Phase 3 | Completed | Cervical Cancer | 793 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02247232) |
| June 23, 2014 | NCT02170311 | Pharmacokinetics, Pharmacodynamics and Safety Study of Z-213 to Iron Deficiency Anemia | Zeria Pharmaceutical | Phase 1 | Completed | Iron Deficiency Anemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02170311) |
| April 17, 2014 | NCT02117258 | Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma | Zeria Pharmaceutical | Phase 2 | Completed | Metastatic Pancreatic Adenocarcinoma | 167 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02117258) |
| November 1, 2013 | NCT01973790 | Phase III, Long-term, Open-label Safety Study of Z-338 | Zeria Pharmaceutical | Phase 3 | Completed | Dyspepsia | 207 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01973790) |
| January 28, 2013 | NCT01776463 | A Healthy Subject Study With Z-360 and Placebo | Zeria Pharmaceutical | Phase 1 | Completed | Healthy Volunteers | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01776463) |
| November 9, 2010 | NCT01237288 | Therapeutic Use of Oral Sodium Phosphate (Z-521) in Primary Hypophosphatemic Rickets | Zeria Pharmaceutical | Phase 3 | Completed | Primary Hypophosphatemic Rickets | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT01237288) |
| September 29, 2008 | NCT00761358 | To Verify the Efficacy of Z-338 in Subjects With Functional Dyspepsia | Zeria Pharmaceutical | Phase 3 | Completed | Functional Dyspepsia | 820 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00761358) |
| August 11, 2008 | NCT00731445 | Phase I/II Study of Z-208 in Advanced Hepatocellular Carcinoma (HCC) | Zeria Pharmaceutical | Phase 1/2 | Completed | Advanced Hepatocellular Carcinoma | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00731445) |
| April 10, 2007 | NCT00458328 | The Effect of Z-338 in Subjects With Functional Dyspepsia | Zeria Pharmaceutical | Phase 2 | Completed | Functioanl Dyspepsia | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00458328) |
| June 5, 2006 | NCT00333372 | To Evaluate the Efficacy of Z-338 in Subjects With Functional Dyspepsia | Zeria Pharmaceutical | Phase 2 | Completed | Functional Dyspepsia | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00333372) |
| May 10, 2006 | NCT00323817 | To Evaluate the Efficacy and Safety in Subjects With Functional Dyspepsia | Zeria Pharmaceutical | Phase 2 | Completed | Functional Dyspepsia | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00323817) |
| March 1, 2006 | NCT00298194 | The Effects of Z-338 in Subjects With and Without Functional Dyspepsia | Zeria Pharmaceutical | Phase 2 | Completed | Dyspepsia | 52 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00298194) |
| February 8, 2006 | NCT00288925 | Z-360 in Unresectable Advanced Pancreatic Cancer in Combination With Gemcitabine Treatment | Zeria Pharmaceutical | Phase 1/2 | Completed | Pancreatic Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00288925) |
| August 31, 2001 | NCT00016692 | Safety and Tolerability of Z-100 in Patients With Early HIV Infection | Zeria Pharmaceutical | Phase 1 | Terminated | HIV Infections | Not listed | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT00016692) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 5 |
| Phase 1/2 | 2 |
| Phase 2 | 7 |
| Phase 3 | 9 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 22 |
| Terminated | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Anemia, Iron-Deficiency | 3 |
| Hyperkalemia | 2 |
| Uterine Cervical Neoplasms | 2 |
| Dyspepsia | 2 |
| Pancreatic Neoplasms | 2 |
| Esophagitis, Peptic | 1 |
| HIV Infections | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Food and beverage consultants in the United States](https://specstream.ai/data/businesses/food-and-beverage-consultants/united-states)
- [Ethiopian restaurants in the United States](https://specstream.ai/data/businesses/ethiopian-restaurants/united-states)
- [Ear, nose and throat clinics in the United States](https://specstream.ai/data/businesses/ear-nose-and-throat-clinics/united-states)
- [Customs brokers in the United States](https://specstream.ai/data/businesses/customs-brokers/united-states)
- [Cocktail bars in the United States](https://specstream.ai/data/businesses/cocktail-bars/united-states)
